Table 1.
Baseline patient demographics and treatment characteristics
| Baseline characteristics | (N=78) |
| Age (years) | |
| Median (range) | 60 (31, 87) |
| Gender | |
| Male | 44 (56%) |
| Baseline ECOG | |
| 0 | 52 (67%) |
| 1 | 24 (31%) |
| ≥2 | 2 (2%) |
| Tumor type | |
| Melanoma | 70 (90%) |
| Other* | 8 (10%) |
| History of autoimmune disease | |
| No | 70 (90%) |
| Yes† | 8 (10%) |
| Treatment setting | |
| Neoadjuvant/adjuvant | 23 (29%) |
| Metastatic/unresectable | 55 (71%) |
| AJCC stage | |
| II/III | 23 (29%) |
| IV | 55 (71%) |
| Immunotherapy type | |
| Combination PD-1/CTLA-4 | 51 (65%) |
| PD-1 alone | 18 (23%) |
| CTLA-4 alone | 9 (12%) |
| Number of ICI cycles | |
| Median (range) | 2 (1, 28) |
*Lung n=4; RCC n=3; prostate n=1
†Inflammatory arthritis n=3; psoriasis n=2; inflammatory bowel disease n=1; hypothyroidism n=1; multiple sclerosis n=1
AJCC, American Joint Committee on Cancer; CTLA-4, cytotoxic T-lymphocytes-associated protein 4; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; PD-1, programmed cell death protein-1.